Navigation Links
Abbott Launches Next-Generation StarClose(R) SE Vascular Closure System
Date:5/15/2008

New Device Designed to Provide Fast, Safe and Secure Vessel Closure

Following Catheterization Procedures

ABBOTT PARK, Ill., May 16 /PRNewswire-FirstCall/ -- Abbott today announced the launch of the StarClose(R) SE Vascular Closure System, a next-generation vessel closure device engineered to enable fast, safe and secure closure of the femoral artery access site following a catheterization procedure. StarClose SE is available in the United States and Europe.

StarClose SE, which stands for "Safe and Extravascular," builds upon the premium design of its predecessor, StarClose, with more ergonomically-friendly design features. StarClose SE advancements include:

-- Improved ease of use, with an intuitive, numbered system, providing

visual guidance and audible "clicks" for each step leading to clip

deployment

-- Immediate vessel closure with deployment of a shape-memory clip onto

the surface of an artery, allowing patients to recover and be

discharged sooner than with manual compression

-- Added device stability for the operator during clip deployment

"With a more ergonomic stabilizer and simpler, numbered-step deployment, StarClose SE offers users the ability to close an artery in a fast, safe and effective manner following a catheterization procedure," said David Lee, M.D., assistant professor of Medicine and director of Cardiac Catheterization and Coronary Intervention Laboratories at the Stanford School of Medicine. "With its definitive mechanical closure, StarClose SE enables an operator to confirm a reliable closure immediately, which offers important benefits for physicians and patients in reducing patient time to mobility following these procedures."

StarClose SE utilizes the same nitinol (nickel and titanium) clip technology as StarClose to close the femoral artery access site after a catheterization procedure. When deployed, the small nitinol clip grasps the tissue on top of the artery around the access site in a purse-string fashion and closes the opening in the femoral artery rapidly and securely with minimal affect to the lumen diameter or the blood flow inside the vessel.

"We are pleased to introduce StarClose SE to advance the secure closure of the vascular access site following catheterization procedures," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs and chief medical officer, Abbott Vascular. "StarClose SE was carefully designed to preserve the safety, reliability and extravascular closure of our first-generation technology, while providing enhanced ease of use for physicians."

For important safety information about StarClose SE, as well as additional information about this product, please refer to Abbott's Web site.

About Catheterization

Catheterization is a procedure commonly used to evaluate or treat certain types of disease in vessels of the heart and other parts of the body. The procedure involves the insertion of a flexible tube, called a catheter, into the femoral artery in the leg. The physician will use the catheter to observe the condition of the coronary or peripheral blood vessels or to treat blockages in the vessels. Following the procedure, the physician will remove the catheter and close the femoral artery access site.

Over the years, a variety of methods, such as direct pressure (manual compression), sandbags and mechanical clamps, have been used to close the puncture site and achieve hemostasis (cessation of bleeding). Many of these methods have proved less than satisfactory, causing patients significant discomfort and requiring up to several hours of bedrest.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... Fairfield, Iowa (PRWEB) , ... June 20, 2017 ... ... a chance to immediately determine the adulterants which pose the most likely threat ... 25 - 28 of this year. , IFT's annual food expo attracts ...
(Date:6/20/2017)... Parsippany, NJ (PRWEB) , ... June 20, 2017 , ... ... OHAUS makes the transition from being a trusted supplier in the weighing industry, to ... including cell extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for ...
(Date:6/19/2017)... ... June 19, 2017 , ... EDETEK, Inc., a ... that it is launching two new additions of its award-winning cloud-based platform CONFORM™: ... at the DIA 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. , ...
(Date:6/16/2017)... ... June 16, 2017 , ... Cognition Corporation , ... two more sessions of its “From the Helm” Webinar Series. , The ... online templates for design control exercises. Led by David Cronin, Cognition’s CEO, the ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):